CCP
BMRN icon

Clough Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clough Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,580
Closed -$252K – 128
2024
Q3 		$252K Hold
3,580
– – 0.03% 128
2024
Q2 		$295K Hold
3,580
– – 0.03% 114
2024
Q1 		$313K Hold
3,580
– – 0.03% 115
2023
Q4 		$345K Hold
3,580
– – 0.04% 165
2023
Q3 		$317K Sell
3,580
-44,390
-93% -$3.95M 0.03% 155
2023
Q2 		$4.16M Buy
+47,970
New +$4.51M 0.42% 72
2019
Q3 		– Sell
-70,689
Closed -$6.05M – 102
2019
Q2 		$6.05M Sell
70,689
-700
-1% -$59.9K 0.59% 62
2019
Q1 		$6.34M Buy
71,389
+10,000
+16% +$927K 0.55% 63
2018
Q4 		$5.23M Buy
61,389
+25,444
+71% +$2.42M 0.61% 59
2018
Q3 		$3.49M Sell
35,945
-4,500
-11% -$449K 0.33% 68
2018
Q2 		$3.81M Buy
40,445
+4,100
+11% +$359K 0.34% 71
2018
Q1 		$2.95M Sell
36,345
-3,100
-8% -$266K 0.28% 76
2017
Q4 		$3.52M Sell
39,445
-9,200
-19% -$800K 0.29% 70
2017
Q3 		$4.53M Sell
48,645
-1,500
-3% -$133K 0.3% 75
2017
Q2 		$4.55M Sell
50,145
-53,364
-52% -$4.85M 0.32% 72
2017
Q1 		$9.09M Buy
103,509
+5,800
+6% +$516K 0.58% 54
2016
Q4 		$8.09M Buy
97,709
+33,509
+52% +$2.88M 0.54% 58
2016
Q3 		$5.94M Buy
64,200
+60,400
+1,589% +$5.69M 0.31% 90
2016
Q2 		$296K Buy
+3,800
New +$323K 0.02% 170

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Clough Capital Partners's BMRN Position: Q4 2024 in Review

Clough Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 3,580 shares — an estimated $252K sold.

Clough Capital Partners first reported a position in BMRN in Q2 2016 and held it in 19 quarters. The position peaked at $9.09M in Q1 2017. 545 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Clough Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Clough Capital Partners sold 3,580 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $252K.
  • Clough Capital Partners first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 19 quarters.
  • Clough Capital Partners's BioMarin Pharmaceuticals position peaked at $9.09M in Q1 2017.
  • 545 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Clough Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.